Arana files IND

By Dylan Bushell-Embling
Tuesday, 30 September, 2008

Arana Therapeutics [ASX: AAH] has submitted an IND to the FDA for its candidate ART621 for rheumatoid arthritis.

As part of the IND application, a Phase II dose trial of the anti-TNF drug will be conducted in a multi-centre trial in 200 patients.

Arana expects to begin recruitment for the study later this year, pending approval from the FDA. Quintiles has been named as the contract research manager.

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

MV Hondius passengers return to Australia under strict infection control measures

The Australian CDC has provided an update on hantavirus risk to Australians and infection...

Content from other channels on our network

CSIRO job cuts cause industry concern

Rittal RiLineX — A standardised 60 mm busbar platform engineered for AS/NZS 61439 switchboards

Renewable energy tender to power a third of NSW homes

Researchers develop new way to recycle plastics

Tassie off-grid pod selected as water prize semi-finalist

Outdated, overused and ineffective — time to end mandatory double-checking?

New Support at Home consumer protection measures announced

Chemical-free cleaning: the future of infection control in health care

Latrobe Regional Health charged after nurse "seriously assaulted" by patient

Charges laid following patient death at The Royal Melbourne Hospital

Submissions open for 2026 Melbourne Royal Food Awards

Swisslog to deliver a second frozen high bay warehouse project for Magnavale

Rockwell Automation releases 2026 State of Smart Manufacturing Report

IFPA A-NZ strengthens board with industry appointments

Weathering the storm: climate resilience in the food & beverage sector